In vitro activity of amikacin against isolates of mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates

Journal of Clinical Microbiology

Volumn 51, Issue 10, 2013, Pages 3389-3394

  Brown Elliott, Barbara A ^a   Iakhiaeva, Elena ^a   Griffith, David E ^b   Woods, Gail L ^c   Stout, Jason E ^d   Wolfe, Cameron R ^d   Turenne, Christine Y ^e   Wallace Jr , Richard J ^a,b  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b UT Health Northeast ^*  (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Saskatchewan Disease Control Laboratory   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CLARITHROMYCIN; ETHAMBUTOL; RIFABUTIN; RNA 16S;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CLINICAL ARTICLE; GENE MUTATION; HUMAN; IN VITRO STUDY; LUNG DISEASE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHIMAERA; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; VARIABLE NUMBER OF TANDEM REPEAT;

AMIKACIN; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; POINT MUTATION; RNA, RIBOSOMAL, 16S;

EID: 84884741628     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01612-13     Document Type: Article

References (19)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr, Winthrop K, ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367-416.
2. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K, Caccitolo J, Alvarez J, Shepherd S, Wilson R, Graviss EA, Wallace RJ, Jr. 2006. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 174:928-934. (Pubitemid 44564794)
3. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. 2012. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist. Updat. 15:149-161.
4. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard, 2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Heifets LB, Lindholm-Levy P. 1989. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob. Agents Chemother. 33: 1298-1301. (Pubitemid 19191975)
6. Gangadharam PRJ, Perumal VK, Podapati NR, Kesavalu L, Iseman MD. 1988. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob. Agents Chemother. 32:1400-1403.
7. Davis KK, Kao PN, Jacobs SS, Ruoss SJ. 2007. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm. Med. 7:2. doi:10.1186/1471-2466-7-2. (Pubitemid 46359485)
8. Iakhiaeva E, McNulty S, Brown-Elliott BA, Falkinham JO, III, Williams MD, Vasireddy R, Wilson RW, Turenne C, Wallace RJ, Jr. 2013. Mycobacterial interspersed repetitive-unit-variable-number tandemrepeat (MIRU-VNTR) genotyping of Mycobacterium intracellulare for strain comparison with establishment of a PCR database. J. Clin. Microbiol. 51:409-416.
9. Wilton S, Cousins D. 1992. Detection and identification of multiple mycobacterial pathogens by DNA amplification in a single tube. PCR Methods Appl. 1:269-273.
10. Wallace RJ, Jr, Iakhiaeva E, Williams MD, Brown-Elliott BA, Vasireddy S, Vasireddy R, Lande L, Peterson DD, Sawicki J, Kwait R, Tichenor WS, Turenne C, Falkinham JO, III. 2013. Absence of Mycobacterium intracellulare and the presence of Mycobacterium chimaera in household water and biofilm samples of patients in the United States with Mycobacterium avium complex respiratory disease. J. Clin. Microbiol. 51:1747-1752.
11. Inagaki T, Nishimori K, Yagi T, Ichikawa K, Moriyama M, Nakagawa T, Shibayama T, Uchiya K, Nikai T, Ogawa K. 2009. Comparison of a variable-number tandem-repeat (VNTR) method for typing Mycobacterium avium with mycobacterial interspersed repetitive-unit-VNTR and IS1245 restriction fragment length polymorphism typing. J. Clin. Microbiol. 47:2156-2164.
12. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. CLSI M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Prammananan T, Sander P, Brown BA, Frischkorn K, Onyi GO, Zhang Y, Böttger EC, Wallace RJ, Jr. 1998. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis. 177:1573-1581. (Pubitemid 28243581)
14. Nash KA, Brown-Elliott BA, Wallace RJ, Jr. 2009. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob. Agents Chemother. 53:1367-1376.
15. Brown-Elliott BA, Nash KA, Wallace RJ, Jr. 2012. Antimicrobial suscep-tibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin. Microbiol. Rev. 25:545-582.
16. Nessar N, Reyrat JM, Murray A, Gicquel B. 2011. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J. Antimicrob. Chemother. 66:1719-1724.
17. Kobashi Y, Matsushima T, Oka M. 2007. A double-blind randomized study of aminoglycosides infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir. Med. 101:130-138. (Pubitemid 44835234)
18. Kobashi Y, Yoshida K, Miyashita N, Oka M. 2006. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J. Infect. Chemother. 12:195-202. (Pubitemid 44327188)
19. Kobashi Y, Abe M, Mouri K, Obase Y, Kato Y, Oka M. 2012. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in recent 6-year period. J. Infect. Chemother. 18: 436-443.